Home › Core › ISCC-IDs › 28CrY973i9TNV

View ISCC-ID

Core Data

28CrY973i9TNV
ISCC-ID - digital asset identifier
CChtzFZ9PVgkm-CTACVAJNASKn4-CDvhXeGtCVKKE-CRe5yXt47bKbR
ISCC-CODE - digital asset descriptor
2QTa5N4aeSrCB2MLoPdPF4AsTjstJgcLTnd
PUBLIC-KEY or WALLET-ADDRESS of DECLARING PARTY
0
Number of times updated

Seed Metadata (Immutable)

o35 patients receiving antitumour necrosis factor therapies experience clinically important improvements in rheumatoid arthritis

Ledger Reference

coblo
Source Ledger/Blockchain
669363
N-th ISCC Decleration on source ledger
0754165dbf2c20c890beb49def73480595d8b19fc2e06be8f69b0d9255ccade2
Hash of block that includes the ISCC-DECLARATION
8854abcb602d351b305603a7868ea9c0e4b2eec266e7831be111e4c2b3f5bc53
Hash of transaction that includes the ISCC-DECLERATION
0
Output index that includes ISCC-DECLERATION (UTXO based chains)

Mutable Metadata

[{"data": {"name": "O35.\u2003Patients Receiving Anti-Tumour Necrosis Factor Therapies Experience Clinically Important Improvements in Rheumatoid Arthritis Related Fatigue: Results from the British Society for Rheumatology Biologics Register", "@type": "ScholarlyArticle", "genre": "journal-article", "author": [{"name": "Katie Druce", "@type": "Person"}, {"name": "Gareth T. Jones", "@type": "Person"}, {"name": "Gary J. Macfarlane", "@type": "Person"}, {"name": "Neil Basu", "@type": "Person"}], "@context": "http://schema.org/", "encoding": [{"@type": "MediaObject", "contentUrl": "https://academic.oup.com/rheumatology/article-pdf/53/suppl_1/i44/9578167/keu091.005.pdf", "encodingFormat": "application/pdf"}], "publisher": {"name": "Oxford University Press (OUP)", "@type": "Organization"}, "identifier": [{"@type": "PropertyValue", "value": "10.1093/rheumatology/keu091.005", "propertyID": "DOI"}, {"@type": "PropertyValue", "value": "CChtzFZ9PVgkm-CTACVAJNASKn4-CDvhXeGtCVKKE-CRe5yXt47bKbR", "propertyID": "ISCC"}], "datePublished": "2014-04-01"}, "schema": "schema.org", "mediatype": "application/ld+json"}]
Close